(S)-(+)-Dimethindene maleate: Practical Guide

(S)-(+)-Dimethindene maleate, SKU B6734, is a research-use small molecule supplied as the maleate salt. The product dossier describes selective affinity for the muscarinic acetylcholine receptor subtype M2, reduced interaction with M1, M3, and M4, and antagonist activity at histamine H1 receptors. Because no directly matched paper evidence is available for this product entry, the guidance below separates documented product attributes from workflow recommendations.

What This Product Solves

Many receptor experiments require a defined antagonist to test whether a response is influenced by M2 muscarinic receptor signaling. B6734 provides a practical starting material for this purpose while also requiring researchers to account for its reported H1 antagonist activity. That dual pharmacology is important when interpreting assays involving airway, vascular, cardiac, neuronal, or other tissues in which histamine responses may contribute to the measured phenotype.

In autonomic regulation research, the compound can be incorporated into comparative antagonist experiments designed to assess the contribution of M2-associated signaling. In cardiovascular physiology studies and respiratory system function research, it may be used as one component of a receptor-selectivity panel rather than as a stand-alone proof of M2 involvement. A muscarinic acetylcholine receptor signaling pathway result should therefore be interpreted together with receptor expression, assay context, vehicle controls, and appropriate H1-related controls.

Evidence boundary

The available dossier supports the compound name, CAS 136152-65-3, salt composition, molecular weight, purity, water solubility statement, and storage guidance. It does not provide a product-specific potency value, binding constant, selectivity ratio, cell-line validation set, species comparison, or functional assay result. Do not infer any of those parameters from the product description.

For related workflow context, read (S)-(+)-Dimethindene maleate: Practical Use in M2 Antagonist Assays; it complements this article with assay-planning considerations rather than supplying direct matched-paper evidence. For a broader receptor-profiling perspective, (S)-(+)-Dimethindene maleate: Reliable Tool for Receptor Profiling can be used as contextual reading, not as confirmation of unreported quantitative performance.

Protocol Parameters

The following parameters distinguish product specifications from recommendations made for experimental planning. The dossier values should be recorded in the study file before preparation.

• Assay: aqueous stock preparation; Value: soluble in water at concentrations ≥20.45 mg/mL; Applicability: initial preparation for aqueous receptor or cell-based assay workflows; Rationale: provides the stated water-solubility reference while leaving final assay concentration and dilution scheme to the investigator; Source type: product specification.
• Assay: molar concentration calculation; Value: 408.5 g/mol; Applicability: conversion between mass-based and molar dosing for the maleate salt; Rationale: using the supplied salt molecular weight prevents errors when reporting exposure or preparing dilution records; Source type: product specification.
• Assay: material qualification; Value: 98.00% purity; Applicability: reagent identity and lot documentation before biological testing; Rationale: purity should be included in the assay record and considered when comparing lots or calculating nominal amounts; Source type: product specification.
• Assay: solid storage; Value: desiccated at room temperature; Applicability: unopened and retained solid material; Rationale: following the stated storage condition limits avoidable exposure to moisture and temperature excursions; Source type: product specification.
• Assay: exposure design; Value: no product-specific concentration range supplied; Applicability: exploratory M2 or H1 antagonist testing; Rationale: establish a study-defined concentration series from the assay system and controls instead of importing an unsupported potency assumption; Source type: workflow recommendation.

Workflow Setup and QC Checklist

Before compound preparation

1. Confirm that the experimental question distinguishes M2-related effects from general muscarinic or histamine responses. Record the receptor model, species or cell background, expression status, readout, and timing plan.
2. Record the product name, SKU B6734, CAS number, lot information, maleate salt form, molecular weight, stated purity, and storage condition. Use the salt molecular weight for all nominal concentration calculations.
3. Define controls before opening the vial. At minimum, include an untreated or vehicle condition and a response control appropriate to the assay. If target attribution is central, add receptor-negative, receptor-matched, or pharmacological comparator conditions that the laboratory has independently validated.

Preparation and addition

Prepare the solution using the stated water-solubility information as a feasibility reference, not as a guarantee of solubility in complete medium, buffered salt solution, serum-containing matrix, or organic co-solvent. Mix gently until the material is visibly uniform. If cloudiness, crystals, or precipitate appear, stop and investigate concentration, matrix compatibility, pH, and mixing before dosing experimental samples.

Solutions are not recommended for long-term storage and should be used promptly. Prepare only the amount needed for the planned run when practical, label the preparation time, and avoid repeated warming, cooling, or unnecessary transfers. If a sterile-filtered solution is required by the assay, validate recovery and adsorption for the selected filter and concentration; the dossier does not establish filter compatibility.

Run-level QC

• Use matched vehicle composition across control and treatment wells or tissue preparations.
• Randomize sample placement when plate position, evaporation, or handling order could influence the readout.
• Inspect the solution and assay matrix for precipitation before dosing and at the end of the exposure period when feasible.
• Predefine acceptance criteria for baseline signal, control response, viability, and assay variability. These are laboratory or assay-specific criteria, not product specifications.
• For a claimed M2-selective interpretation, compare the result with relevant M1, M3, M4, and H1 controls where those systems are available. A response that disappears only in one model is not by itself proof of receptor selectivity.
• Archive preparation calculations, dilution steps, appearance observations, timing, plate map, raw signal, exclusions, and deviations from the planned protocol.

Common Failure Modes and Fixes

• Free-base and salt confusion: Calculating from an assumed free-base molecular weight can misstate the delivered molarity. Fix the calculation basis to the documented maleate salt molecular weight of 408.5 g/mol and report it clearly.
• Overstated M2 selectivity: The dossier describes reduced interaction with M1, M3, and M4, not absolute exclusivity, and also reports H1 antagonism. Fix the interpretation by using cautious language and adding receptor-relevant controls.
• Precipitation after dilution: A solution that appears clear in water may behave differently after transfer into assay medium. Fix this by checking the final matrix, using a validated mixing order, and documenting visible instability rather than treating the nominal dose as confirmed exposure.
• Loss of reproducibility from stored solutions: Long-term solution storage is not recommended. Fix this by preparing fresh working material promptly and recording preparation and use times.
• Uninterpretable vehicle effects: Changes in solvent, ionic strength, or pH can resemble antagonist activity. Fix this with matched vehicle controls and a matrix-only control where appropriate.
• Unsupported potency claims: No matched paper or product-specific potency dataset is supplied here. Fix this by describing the experiment as exploratory until the laboratory generates validated concentration-response and selectivity data.

Scope and Limitations

(S)-(+)-Dimethindene maleate is appropriate for scientific research use involving pharmacological assay development, receptor profiling, and selected autonomic, cardiovascular, or respiratory models. The available information supports its use as a defined research reagent with reported M2 and H1 antagonist activity, but it does not establish performance in a particular cell line, tissue, animal model, or clinical setting.

Researchers should not infer binding affinity, functional efficacy, receptor occupancy, exposure stability, permeability, toxicity thresholds, or in vivo activity without independent measurements. The water-solubility statement also does not replace a formulation study in the final assay matrix. The product is not intended for diagnostic or medical purposes. Any H1 contribution, off-target effect, assay interference, or matrix-dependent behavior must be evaluated within the chosen experimental system.

Conclusion

B6734 offers a documented maleate salt form of (S)-(+)-Dimethindene maleate for studies requiring an M2 muscarinic receptor antagonist with reported H1 activity. A reproducible workflow should use the stated molecular weight, purity, solubility, and storage conditions; prepare solutions promptly; inspect for precipitation; match vehicles; and avoid treating receptor selectivity or potency as proven beyond the available dossier. In the absence of directly matched paper evidence, careful controls and transparent QC records are essential for defensible conclusions.